December 29, 2014 6:35 AM ET

Biotechnology

Company Overview of Ardea Biosciences, Inc.

Company Overview

Ardea Biosciences, Inc., a biotechnology company, focuses on the discovery and development of small-molecule therapeutics for the treatment of gout and cancer in the United States. Its product candidates include Lesinurad (RDEA594), an inhibitor of the URAT1 kidney transporter, which is in Phase III clinical trials for the treatment of gout; BAY 86-9766 (RDEA119), a mitogen-activated ERK kinase (MEK) inhibitor that is in Phase II clinical trials for the treatment of cancer; and RDEA3170, an URAT1 kidney transporter inhibitor, which is in Phase I clinical trials for the treatment of gout. The company has a development and commercialization license agreement with Bayer Healthcare AG to develop...

4939 Directors Place

San Diego, CA 92121

United States

107 Employees

Phone:

858-652-6500

Fax:

858-625-0760

Key Executives for Ardea Biosciences, Inc.

President and Chief Operating Officer
Chief Financial Officer
Age: 54
Senior Vice President of Regulatory Affairs & Development Operations
Age: 54
Senior Vice President of Pharmaceutical Sciences
Age: 50
Vice President of Preclinical Development
Compensation as of Fiscal Year 2014.

Ardea Biosciences, Inc. Key Developments

Astrazeneca and Ardea Biosciences Presents Results from Study of allopurinol

AstraZeneca and Ardea Biosciences presented results from a large study of allopurinol, a treatment commonly used to lower uric acid in patients with gout. The LASSO (Long-term Allopurinol Safety Study evaluating Outcomes in gout patients) study was a multinational, 6-month, open, prospective observational study involving 1,735 patients with gout and was designed to evaluate the safety and efficacy of medically appropriate doses of allopurinol. Results of the LASSO study showed no new safety signals with allopurinol doses of approximately 300mg/day. The study also revealed that at the time of last dose fewer than half (43%) of patients taking allopurinol achieved the target serum uric acid (sUA) level of <6.0 mg/dL, the level recommended by the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR). Specific findings from LASSO include: The study revealed no new safety signals with allopurinol (approximately 300mg/day). There were no cases of allopurinol hypersensitivity syndrome in this study. At the time of last dose 43% of all patients in the study achieved target sUA levels of <6.0 mg/dL. of patients in the study at final doses above 300mg/day, approximately 54% achieved target sUA levels of <6.0 mg/dL.

Similar Private Companies By Industry

Company Name Region
Dominion Biosciences, Inc. United States
Cima Labs Inc. United States
Sequella, Inc. United States
Pacific Biotech, Inc. United States
Seres Health, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Ardea Biosciences, Inc., please visit www.ardeabio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.